0 Items
Select Page

Human Metapneumovirus

Human Metapneumovirus (HMPV), along with Respiratory Syncytial Virus (RSV), is a common cause of lower respiratory tract infection in children worldwide. HMPV is an enveloped, negative single-stranded RNA virus belonging to the genus Metapneumovirus, of the family Pneumoviridae. The virus can affect the upper and lower respiratory tract of children and adults but can cause severe disease in children, the elderly and immunocompromised patients.

The Native Antigen Company offers highly specific HMPV monoclonal antibodies to support research and immunoassay development.

Human Metapneumovirus Background

Human Metapneumovirus (HMPV) is an enveloped, negative single-stranded RNA virus belonging to the genus Metapneumovirus, of the family Pneumoviridae. HPMV is closely related to Respiratory Syncytial virus (RSV), which belongs to the genus Orthopneumovirus within the same family (Alfonso, CL).

Human Metapneumovirus is globally widespread and is seasonal in temperate climates, being most active from winter to spring. Genomic analysis has shown that HMPV exists as two genotypes A and B, which are further divided into subgroups A1, A2 and B1, B2. Each of these subgroups has a distinct geographical distribution but may circulate separately or concurrently (Boivin, G).

Transmission of HMPV from person-to-person predominantly occurs through contact with airborne droplets from an infected individual, produced by coughing or sneezing. It can also be spread through contact with contaminated hands or surfaces.

Identified in 2001, HMPV, is one of the most common causes of paediatric lower respiratory tract infection. However, the virus can affect individuals of all ages infecting the upper or lower respiratory tract. The symptoms of HMPV infection include coughing, fever, wheezing and shortness of breath but in some cases bronchitis or pneumonia can develop. HMPV can cause severe life-threatening illness in paediatric, geriatric and immunocompromised patients (CDC).

Diagnosis of HMPV infection is commonly performed using molecular and serological techniques. Currently, there is no licensed vaccine available for the prevention of human Metapneumovirus infection and no antiviral treatment for the disease.

References

Afonso CL et al. 2016. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. Aug;161(8):2351-60

Boivin G et al. 2004. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis. Jun;10(6):1154-7

Centers for Disease Control and Prevention: The national respiratory virus and enteric virus surveillance system. Human metapneumovirus (HMPV) clinical features.

The Native Antigen company offers monoclonal antibodies specific to the Human Metapneumovirus (HMPV) and which are suitable for the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

7 + 8 =

Live Customer Feedback

Join our mailing list

* indicates required